Furthermore, givinostat (also indicated as ITF2357) inhibited in vitro insulin resistance and the apoptosis of pancreatic cells, counteracting the detrimental effects of insulin resistance mechanisms, which can lead to T2DM and obesity development, and, in addition, this drug normalized streptozotocin (STZ)-induced hyperglycemia conditions in vivo [55]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.